Rome, 29 Dec. (beraking latest news) – The AIFA determines the methods and conditions of use of the antiviral ‘Lagevrio’ (molnupiravir) produced by the Merck company for the treatment of Covid “in adult patients not hospitalized for Covid-19 with mild-moderate disease of recent onset and with concomitant clinical conditions that represent specific risk factors for the development of severe Covid-19 “. This is what we read in the Official Gazette.
The antiviral, it says, “is used in compliance with the following methods: the selection of the patient is entrusted to general practitioners, to the doctors of Usca (r) and, in general, to doctors who have the opportunity to enter contact with patients suffering from Covid recently onset and with mild-moderate symptoms and to quickly direct them to the facility where to carry out the prescription with compilation of the monitoring register and the distribution of the drug which must take place in compliance with the criteria set by the CTS, and indicated in the register, pursuant to art.2; the prescription of the product is limited to doctors operating in the structures identified by the regions for administration; the prescription and treatment must guarantee the administration of the product as soon as possible possible with respect to the onset of symptoms, and in any case no later than five days from the beginning of the same; health professionals in management of the treatment take into account the information contained in annexes 1 and 2, which form an integral part of this determination “.
The definition of the path through which patients eligible for treatment are identified, we read, “is left to the provisions of the regions and autonomous provinces”.